Its main function is transporting long-chain fatty acids into mitochondria, the energy-producing centers in your cells, where these fats are burned for fuel
Market Drivers : Growth is driven by the rising prevalence of obesity and Type 2 diabetes, the shift toward incretin-based therapies, expanding clinical evidence of weight-loss benefits, and improved patient awareness, supported by physician advocacy and digital health engagement
While this approach may work short term, it often triggers the bodys natural defense mechanisms
27 Similarly, a different group (Morningstar Equities) predicts that GLP-1 prices could begin to fall 10%-15% per year beginning in 2027
In short: Lilly is likely unwilling to cannibalize its injectables franchise
doi: 10.1016/j.joca.2020.02.103 21